Literature DB >> 29747838

High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.

Robert Stöhr, Lukas Sandstede, Gunnar H Heine, Nikolaus Marx, Vincent Brandenburg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29747838     DOI： 10.1016/j.jacc.2018.03.448

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  10 in total

1.  Randomized trial of intravenous iron-induced hypophosphatemia.

Authors:  Myles Wolf; Glenn M Chertow; Iain C Macdougall; Robert Kaper; Julie Krop; William Strauss
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Drug-Induced Hypophosphatemia: Current Insights.

Authors:  Efstathia Megapanou; Matilda Florentin; Haralampos Milionis; Moses Elisaf; George Liamis
Journal:  Drug Saf       Date:  2020-03       Impact factor: 5.606

3.  Short-term treatment of iron deficiency anemia after cardiac surgery.

Authors:  Elio Venturini; Gabriella Iannuzzo; Anna DI Lorenzo; Gianluigi Cuomo; Andrea D'Angelo; Pasquale Merone; Giuseppe Cudemo; Mario Pacileo; Antonello D'Andrea; Carlo Vigorito; Francesco Giallauria
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-02

Review 4.  Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review.

Authors:  John A Glaspy; Michelle Z Lim-Watson; Michael A Libre; Swagata S Karkare; Nandini Hadker; Aleksandra Bajic-Lucas; William E Strauss; Naomi V Dahl
Journal:  Ther Clin Risk Manag       Date:  2020-04-08       Impact factor: 2.423

5.  Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice.

Authors:  Toby Richards; Christian Breymann; Matthew J Brookes; Stefan Lindgren; Iain C Macdougall; Lawrence P McMahon; Malcolm G Munro; Elizabeta Nemeth; Giuseppe M C Rosano; Ingolf Schiefke; Günter Weiss
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

Review 6.  Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology.

Authors:  Ridha I S Alnuwaysir; Martijn F Hoes; Dirk J van Veldhuisen; Peter van der Meer; Niels Grote Beverborg
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.964

7.  High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.

Authors:  Johannes M M Boots; Rogier A M Quax
Journal:  Drug Saf       Date:  2022-09-06       Impact factor: 5.228

8.  Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure.

Authors:  Haye H van der Wal; Niels Grote Beverborg; Jozine M Ter Maaten; Joanna S J Vinke; Martin H de Borst; Dirk J van Veldhuisen; Adriaan A Voors; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2020-04-03       Impact factor: 15.534

9.  A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose.

Authors:  Giuseppe Rosano; Ingolf Schiefke; Udo-Michael Göhring; Vincent Fabien; Stefano Bonassi; Jürgen Stein
Journal:  J Clin Med       Date:  2020-11-06       Impact factor: 4.241

10.  Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage.

Authors:  Vincent Brandenburg; Gunnar H Heine; Nikolaus Marx; Robert Stöhr
Journal:  Clin Res Cardiol       Date:  2020-03-25       Impact factor: 5.460
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.